Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1989 Jan;86(1):322–326. doi: 10.1073/pnas.86.1.322

Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase.

H Satoh 1, B M Martin 1, A H Schulick 1, D D Christ 1, J G Kenna 1, L R Pohl 1
PMCID: PMC286456  PMID: 2911577

Abstract

Previous studies have demonstrated that patients with halothane-induced hepatitis have serum antibodies that are directed against novel liver microsomal neoantigens and have suggested that these neoantigens may play an immunopathological role in development of the patients' liver damage. These investigations have further revealed that the antibodies are directed against distinct polypeptide fractions (100 kDa, 76 kDa, 59 kDa, 57 kDa, 54 kDa) that have been covalently modified by the reactive trifluoroacetyl halide metabolite of halothane. In this paper, the trifluoroacetylated (TFA) 59-kDa neoantigen (59-kDa-TFA) recognized by the patients' antibodies was isolated from liver microsomes of halothane-treated rats by chromatography on an immunoaffinity column of anti-TFA IgG. Antibodies were raised against the 59-kDa-TFA protein and were used to purify the native protein from liver microsomes of untreated rats. Based upon its apparent monomeric molecular mass, NH2-terminal amino acid sequence, catalytic activity, and other physical properties, the protein has been identified as a previously characterized microsomal carboxylesterase (EC 3.1.1.1). A similar strategy may be used to purify and characterized neoantigens associated with other drug toxicities that are believed to have an immunopathological basis.

Full text

PDF
322

Images in this article

323Image
on p.323
324Image
on p.324
325Image
on p.325
325Image
on p.325
325Image
on p.325
325Image
on p.325
325Image
on p.325
325Image
on p.325
325Image
on p.325
325Image
on p.325
325Image
on p.325
325Image
on p.325
325Image
on p.325

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caldwell J., Marsh M. V. Interrelationships between xenobiotic metabolism and lipid biosynthesis. Biochem Pharmacol. 1983 Jun 1;32(11):1667–1672. doi: 10.1016/0006-2952(83)90107-7. [DOI] [PubMed] [Google Scholar]
  2. Christ D. D., Satoh H., Kenna J. G., Pohl L. R. Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. Drug Metab Dispos. 1988 Jan-Feb;16(1):135–140. [PubMed] [Google Scholar]
  3. Faed E. M. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev. 1984;15(5-6):1213–1249. doi: 10.3109/03602538409033562. [DOI] [PubMed] [Google Scholar]
  4. Fraser J. M., Kaminsky L. S. Metabolism of 2,2,2-trifluoroethanol and its relationship to toxicity. Toxicol Appl Pharmacol. 1987 Jun 30;89(2):202–210. doi: 10.1016/0041-008x(87)90041-x. [DOI] [PubMed] [Google Scholar]
  5. Harano T., Miyata T., Lee S., Aoyagi H., Omura T. Biosynthesis and localization of rat liver microsomal carboxyesterase E1. J Biochem. 1988 Jan;103(1):149–155. doi: 10.1093/oxfordjournals.jbchem.a122221. [DOI] [PubMed] [Google Scholar]
  6. Hubbard A. K., Roth T. P., Gandolfi A. J., Brown B. R., Jr, Webster N. R., Nunn J. F. Halothane hepatitis patients generate an antibody response toward a covalently bound metabolite of halothane. Anesthesiology. 1988 May;68(5):791–796. doi: 10.1097/00000542-198805000-00021. [DOI] [PubMed] [Google Scholar]
  7. Kenna J. G., Neuberger J., Williams R. Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. J Pharmacol Exp Ther. 1987 Aug;242(2):733–740. [PubMed] [Google Scholar]
  8. Kenna J. G., Satoh H., Christ D. D., Pohl L. R. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther. 1988 Jun;245(3):1103–1109. [PubMed] [Google Scholar]
  9. Korza G., Ozols J. Complete covalent structure of 60-kDa esterase isolated from 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced rabbit liver microsomes. J Biol Chem. 1988 Mar 5;263(7):3486–3495. [PubMed] [Google Scholar]
  10. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  11. Martin B. M., Tsuji S., LaMarca M. E., Maysak K., Eliason W., Ginns E. I. Glycosylation and processing of high levels of active human glucocerebrosidase in invertebrate cells using a baculovirus expression vector. DNA. 1988 Mar;7(2):99–106. doi: 10.1089/dna.1988.7.99. [DOI] [PubMed] [Google Scholar]
  12. Matsudaira P. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem. 1987 Jul 25;262(21):10035–10038. [PubMed] [Google Scholar]
  13. McLean L. R., Demel R. A., Socorro L., Shinomiya M., Jackson R. L. Mechanism of action of lipoprotein lipase. Methods Enzymol. 1986;129:738–763. doi: 10.1016/0076-6879(86)29102-8. [DOI] [PubMed] [Google Scholar]
  14. Mentlein R., Heiland S., Heymann E. Simultaneous purification and comparative characterization of six serine hydrolases from rat liver microsomes. Arch Biochem Biophys. 1980 Apr 1;200(2):547–559. doi: 10.1016/0003-9861(80)90386-0. [DOI] [PubMed] [Google Scholar]
  15. Neuberger J., Kenna J. G. Halothane hepatitis: a model of immune mediated drug hepatotoxicity. Clin Sci (Lond) 1987 Mar;72(3):263–270. doi: 10.1042/cs0720263. [DOI] [PubMed] [Google Scholar]
  16. Park B. K., Coleman J. W., Kitteringham N. R. Drug disposition and drug hypersensitivity. Biochem Pharmacol. 1987 Mar 1;36(5):581–590. [PubMed] [Google Scholar]
  17. Parker C. W. Allergic reactions in man. Pharmacol Rev. 1982 Mar;34(1):85–104. [PubMed] [Google Scholar]
  18. Pohl L. R., Satoh H., Christ D. D., Kenna J. G. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol. 1988;28:367–387. doi: 10.1146/annurev.pa.28.040188.002055. [DOI] [PubMed] [Google Scholar]
  19. Satoh H., Fukuda Y., Anderson D. K., Ferrans V. J., Gillette J. R., Pohl L. R. Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes. J Pharmacol Exp Ther. 1985 Jun;233(3):857–862. [PubMed] [Google Scholar]
  20. Satoh H., Gillette J. R., Davies H. W., Schulick R. D., Pohl L. R. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. Mol Pharmacol. 1985 Nov;28(5):468–474. [PubMed] [Google Scholar]
  21. Sipes I. G., Gandolfi A. J., Pohl L. R., Krishna G., Brown B. R., Jr Comparison of the biotransformation and hepatotoxicity of halothane and deuterated halothane. J Pharmacol Exp Ther. 1980 Sep;214(3):716–720. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES